Key Takeaways:
New York-based law firm Kirby McInerney LLP has launched an investigation into Qiagen N.V. (QGEN) for potential securities fraud, following an 11 percent drop in the company's share price.
The investigation concerns whether Qiagen and its senior management violated federal securities laws by making misleading statements about its QuantiFERON product, according to a press release from the firm.
On February 5, 2026, Qiagen projected its QuantiFERON product would see growth between 6 and 7 percent for the year. However, on April 27, the company revealed preliminary first-quarter results showing QuantiFERON sales had declined approximately 5 percent on a constant currency basis. The news sent the stock down from $38.09 to $34.02 on April 28.
The investigation could lead to a class-action lawsuit, exposing Qiagen to significant legal costs and potential financial penalties. The discrepancy between the company's initial forecast and the actual results has raised questions about the accuracy of its disclosures to investors.
Kirby McInerney is a New York-based plaintiffs’ law firm specializing in securities, antitrust, whistleblower, and consumer litigation. The firm has encouraged Qiagen investors with relevant information to contact them to discuss their rights.
The investigation introduces significant legal and financial uncertainty for Qiagen, potentially impacting its stock performance until the matter is resolved. Investors will be closely watching for the filing of a formal lawsuit or a response from the company.
This article is for informational purposes only and does not constitute investment advice.
